Abstract Narcolepsy type 1 (NT1) and type 2 (NT2), also known as narcolepsy with and
without cataplexy, are sleep disorders that benefited from major scientific advances over the …

Healthy sleep is vital for humans to achieve optimal health and longevity. Poor sleep and
sleep disorders are strongly associated with increased morbidity and mortality. However, the …

Pitolisant, a novel histamine H3‐receptor antagonist, holds significant promise for treating
narcolepsy. However, a petition, which highlighted that pitolisant was associated with deaths …

Background and Objectives Narcolepsy type 1 (NT1) is due to the loss of hypothalamic
neurons that produce orexin (ORX), by a suspected immune-mediated process. Rare …

Melatonin is a key circadian mediator that governs the synchronisation of peripheral
biological rhythms with the central clock (ie, the suprachiasmatic nucleus) and regulates the …

Background Excessive daytime sleepiness (EDS) is one of the most common non-motor
symptoms in Parkinson's disease (PD). Previous studies showed that PD patients with EDS …

Background Narcolepsy Type I (NT1) is a rare, life-long sleep disorder arising as a
consequence of the extensive destruction of orexin-producing hypothalamic neurons. The …

Narcolepsy is a rare cause of hypersomnolence and may be associated or not with
cataplexy, ie sudden muscle weakness. These forms are designated narcolepsy-type 1 …

Narcolepsy type 1 (NT1) is an enigmatic sleep disorder characterized by the selective loss of
neurons producing orexin (also named hypocretin) in the lateral hypothalamus. Although …

Nearly 25 years have passed since the ground-breaking discovery that hypocretin
deficiency underlies human narcolepsy with cataplexy. Over time, it has become …